title: Long-term effects of insulin-like growth factor (IGF)-I on serum IGF-I, IGF-binding protein-3 and acid labile subunit in Laron syndrome patients with normal growth hormone binding protein.
abstract: A minority of patients with Laron syndrome have normal serum GH binding protein (GHBP), indicating that the defect is elsewhere than in the extracellular domain of the GH receptor. We have evaluated the effect of long-term IGF-I treatment on serum IGF-binding protein (IGFBP)-3 and the acid-labile subunit (ALS) in three sibling with Laron syndrome caused by a GH post-receptor defect and with normal GHBP. The children (a boy aged 3 years, a girl aged 4 years and a boy aged 10 years) were treated by daily s.c. injection of IGF-I in a dose of 150 micrograms/kg. IGFBP-3 was measured by RIA and Western ligand blotting, ALS by RIA. Based values of IGFBP-3 and ALS were low. During IGF-I treatment, the IGFBP-3 concentrations in the girl gradually increased, whereas in the boys there was a 60% decrease during the first week, followed by gradual increase towards baseline. The ALS concentrations followed a similar pattern. We conclude that IGF-I treatment induces and initial suppression and then an increase in the IGFBP-3 and ALS concentrations, confirming data from animal experiments that IGFBP-3 synthesis is not solely under GH control. The differences in responsiveness between the female and male siblings may reflect genetic differences, or lower circulating concentrations of IGF-I in the boys compared with the girl.
authors.affiliation: Institute of Endocrinology, Chaim Sheba Medical Center, Tel Hashomer, Israel.
authors.forename: H
authors.initials: H
authors.lastname: Kanety
authors.forename: A
authors.initials: A
authors.lastname: Silbergeld
authors.forename: B
authors.initials: B
authors.lastname: Klinger
authors.forename: A
authors.initials: A
authors.lastname: Karasik
authors.forename: R C
authors.initials: RC
authors.lastname: Baxter
authors.forename: Z
authors.initials: Z
authors.lastname: Laron
mesh_terms: D002352:Carrier Proteins / Q000097:blood*; D002648:Child; D004392:Dwarfism / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D006023:Glycoproteins / Q000097:blood*; D006801:Humans; D007223:Infant; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood*; D007334:Insulin-Like Growth Factor I / Q000627:therapeutic use*; D008297:Male; D010375:Pedigree; D013997:Time Factors
chemical_list: D002352:Carrier Proteins; D006023:Glycoproteins; D018972:Insulin-Like Growth Factor Binding Protein 3; C075944:insulin-like growth factor binding protein, acid labile subunit; D007334:Insulin-Like Growth Factor I